Clinical symptoms, biochemistry, and liver histology during the native liver period of progressive familial intrahepatic cholestasis type 2.
BSEP
Liver transplantation
NaPB
Pediatric liver disease
Ultra-rare diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
22
05
2023
accepted:
05
02
2024
medline:
11
2
2024
pubmed:
11
2
2024
entrez:
10
2
2024
Statut:
epublish
Résumé
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an ultra-rare disease caused by mutations in the ABCB11 gene. This study aimed to understand the course of PFIC2 during the native liver period. From November 2014 to October 2015, a survey to identify PFIC2 patients was conducted in 207 hospitals registered with the Japanese Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Investigators retrospectively collected clinical data at each facility in November 2018 using pre-specified forms. Based on the biallelic pathogenic variants in ABCB11 and/or no hepatic immunohistochemical detection of BSEP, 14 Japanese PFIC2 patients were enrolled at seven facilities. The median follow-up was 63.2 [47.7-123.3] months. The median age of disease onset was 2.5 [1-4] months. Twelve patients underwent living donor liver transplantation (LDLT), with a median age at LDLT of 9 [4-57] months. Two other patients received sodium 4-phenylbutyrate (NaPB) therapy and survived over 60 months with the native liver. No patients received biliary diversion. The cases that resulted in LDLT had gradually deteriorated growth retardation, biochemical tests, and liver histology since the initial visit. In the other two patients, jaundice, growth retardation, and most of the biochemical tests improved after NaPB therapy was started, but pruritus and liver fibrosis did not. Japanese PFIC2 patients had gradually worsening clinical findings since the initial visit, resulting in LDLT during infancy. NaPB therapy improved jaundice and growth retardation but was insufficient to treat pruritus and liver fibrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an ultra-rare disease caused by mutations in the ABCB11 gene. This study aimed to understand the course of PFIC2 during the native liver period.
METHODS
METHODS
From November 2014 to October 2015, a survey to identify PFIC2 patients was conducted in 207 hospitals registered with the Japanese Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Investigators retrospectively collected clinical data at each facility in November 2018 using pre-specified forms.
RESULTS
RESULTS
Based on the biallelic pathogenic variants in ABCB11 and/or no hepatic immunohistochemical detection of BSEP, 14 Japanese PFIC2 patients were enrolled at seven facilities. The median follow-up was 63.2 [47.7-123.3] months. The median age of disease onset was 2.5 [1-4] months. Twelve patients underwent living donor liver transplantation (LDLT), with a median age at LDLT of 9 [4-57] months. Two other patients received sodium 4-phenylbutyrate (NaPB) therapy and survived over 60 months with the native liver. No patients received biliary diversion. The cases that resulted in LDLT had gradually deteriorated growth retardation, biochemical tests, and liver histology since the initial visit. In the other two patients, jaundice, growth retardation, and most of the biochemical tests improved after NaPB therapy was started, but pruritus and liver fibrosis did not.
CONCLUSIONS
CONCLUSIONS
Japanese PFIC2 patients had gradually worsening clinical findings since the initial visit, resulting in LDLT during infancy. NaPB therapy improved jaundice and growth retardation but was insufficient to treat pruritus and liver fibrosis.
Identifiants
pubmed: 38341604
doi: 10.1186/s13023-024-03080-6
pii: 10.1186/s13023-024-03080-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP17ak0101036
Organisme : Japan Agency for Medical Research and Development
ID : JP19ek0109298
Informations de copyright
© 2024. The Author(s).
Références
Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273(16):10046–50.
doi: 10.1074/jbc.273.16.10046
pubmed: 9545351
Jansen PLM, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJEJ, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology. 1999;117(6):1370–9.
doi: 10.1016/S0016-5085(99)70287-8
pubmed: 10579978
Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20(3):233–8.
doi: 10.1038/3034
pubmed: 9806540
Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;8(4):1.
doi: 10.1186/1750-1172-4-1
Shagrani M, Burkholder J, Broering D, Abouelhoda M, Faquih T, El-Kalioby M, et al. Genetic profiling of children with advanced cholestatic liver disease. Clin Genet. 2017;92(1):52–61.
doi: 10.1111/cge.12959
pubmed: 28039895
van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020;73(1):84–93.
doi: 10.1016/j.jhep.2020.02.007
pubmed: 32087350
Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44(2):478–86.
doi: 10.1002/hep.21287
pubmed: 16871584
Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis. 2011;31(1):3–10.
doi: 10.1055/s-0031-1272831
pubmed: 21344347
Zen Y, Kondou H, Nakazawa A, Tanikawa K, Hasegawa Y, Bessho K, et al. Proposal of a liver histology-based scoring system for bile salt export pump deficiency. Hepatol Res. 2020;50(6):754–62.
doi: 10.1111/hepr.13494
pubmed: 32073700
Bull LN, Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Dodge JL, et al. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies. Hepatol Commun. 2018;2(5):515–28.
doi: 10.1002/hep4.1168
pubmed: 29761168
pmcid: 5944593
Maggiore G, Gonzales E, Sciveres M, Redon M-J, Grosse B, Stieger B, et al. Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2. J Hepatol. 2010;53(5):981–6.
doi: 10.1016/j.jhep.2010.05.025
pubmed: 20800306
Jara P, Hierro L, Martínez-Fernández P, Alvarez-Doforno R, Yánez F, Diaz MC, et al. Recurrence of bile salt export pump deficiency after liver transplantation. N Engl J Med. 2009;361(14):1359–67.
doi: 10.1056/NEJMoa0901075
pubmed: 19797282
Keitel V, Burdelski M, Vojnisek Z, Schmitt L, Häussinger D, Kubitz R. De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis. Hepatology. 2009;50(2):510–7.
doi: 10.1002/hep.23083
pubmed: 19642168
Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830–42.
doi: 10.1016/S2468-1253(22)00093-0
pubmed: 35780807
Loomes KM, Squires RH, Kelly D, Rajwal S, Soufi N, Lachaux A, et al. Maralixibat for the treatment of PFIC: long-term, IBAT inhibition in an open-label, Phase 2 study. Hepatol Commun. 2022;6(9):2379–90.
doi: 10.1002/hep4.1980
pubmed: 35507739
pmcid: 9426380
Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology. 2007;45(6):1506–16.
doi: 10.1002/hep.21630
pubmed: 17538928
Hayashi H, Takada T, Suzuki H, Akita H, Sugiyama Y. Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11. Hepatology. 2005;41(4):916–24.
doi: 10.1002/hep.20627
pubmed: 15791618
Naoi S, Hayashi H, Inoue T, Tanikawa K, Igarashi K, Nagasaka H, et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr. 2014;164(5):1219-1227.e3.
doi: 10.1016/j.jpeds.2013.12.032
pubmed: 24530123
Gonzales E, Grosse B, Schuller B, Davit-Spraul A, Conti F, Guettier C, et al. Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: evidence for improvement of cholestasis with 4-phenylbutyrate. Hepatology. 2015;62(2):558–66.
doi: 10.1002/hep.27767
pubmed: 25716872
Nakano S, Osaka S, Sabu Y, Minowa K, Hirai S, Kondou H, et al. Effect of food on the pharmacokinetics and therapeutic efficacy of 4-phenylbutyrate in progressive familial intrahepatic cholestasis. Sci Rep. 2019;9(1):17075.
doi: 10.1038/s41598-019-53628-x
pubmed: 31745229
pmcid: 6863819
Togawa T, Sugiura T, Ito K, Endo T, Aoyama K, Ohashi K, et al. Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing. J Pediatr. 2016;171:171–7.
doi: 10.1016/j.jpeds.2016.01.006
pubmed: 26858187
Isojima T, Kato N, Ito Y, Kanzaki S, Murata M. Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey. Clin Pediatr Endocrinol. 2016;25(2):71–6.
doi: 10.1297/cpe.25.71
pubmed: 27212799
pmcid: 4860518
Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim M-S, Kim KH, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7(1):10713.
doi: 10.1038/ncomms10713
pubmed: 26888176
pmcid: 4759630
Masahata K, Uehara S, Ibuka S, Nakahata K, Hasegawa Y, Kondou H, et al. Recurrence of progressive familial intrahepatic cholestasis type 2 phenotype after living-donor liver transplantation: a case report. Transplant Proc. 2016;48(9):3156–62.
doi: 10.1016/j.transproceed.2016.02.067
pubmed: 27932171
Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol. 2010;53(1):170–8.
doi: 10.1016/j.jhep.2010.01.034
pubmed: 20447715
pmcid: 3042805
Gounden V, Vashisht R, Jialal I. Hypoalbuminemia. Treasure Island: StatPearls Publishing; 2022.
Lala V, Zubair M, Minter DA. Liver function tests. Treasure Island: StatPearls Publishing; 2022.
Gray SJ, Barron ES. The electrophoretic analyses of the serum proteins in diseases of the liver. J Clin Investig. 1943;22(2):191–200.
doi: 10.1172/JCI101382
pubmed: 16694993
pmcid: 435226
Imagawa K, Hayashi H, Sabu Y, Tanikawa K, Fujishiro J, Kajikawa D, et al. Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis. J Hum Genet. 2018;63(5):569–77.
doi: 10.1038/s10038-018-0431-1
pubmed: 29507376
Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5):1645–55.
doi: 10.1002/hep.23539
pubmed: 20232290
Pfister E-D, Jaeger VK, Karch A, Shay D, Schukfeh N, Ohlendorf J, et al. Native liver survival in bile salt export pump deficiency: results of a retrospective cohort study. Hepatol Commun. 2023;7(4):e0092. https://doi.org/10.1097/HC9.0000000000000092 .
doi: 10.1097/HC9.0000000000000092
pubmed: 36995996
pmcid: 10069862